Poly (ADP-Ribose) polymerase-1 (PARP-1) as immune regulator

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 11, Issue 4, 2011, Pages 326-333

  Laudisi, Federica ^a   Sambucci, Manolo ^a   Pioli, Claudio ^a  

^a ENEA   (Italy)

Author keywords

Adaptive immunity; Immune mediated diseases; Inflammation; PARP 1

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; CD3 ANTIGEN; CD4 ANTIGEN; DOUBLE STRANDED DNA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INO 1001; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PADGEM PROTEIN; RANTES; SINGLE STRANDED DNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALSARTAN;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL PROTECTION; COLITIS; CYTOKINE RELEASE; DENDRITIC CELL; EFFECTOR CELL; ENZYME INHIBITION; GASTRITIS; GENOMIC INSTABILITY; HEART INFARCTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; NONHUMAN; PROTEIN DNA BINDING; PROTEIN FAMILY; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; RHEUMATIC DISEASE; SENSOR; SEPTIC SHOCK; SIGNAL TRANSDUCTION; STROKE; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; TRANSCRIPTION REGULATION;

EID: 80055121810     PISSN: 18715303     EISSN: 18715303     Source Type: Journal    
DOI: 10.2174/187153011797881184     Document Type: Article

References (86)

1. Mazen, A.; Menissier-de Murcia, J.; Molinete, M.; Simonin, F.; Gradwohl, G.; Poirier, G. and de Murcia, G. (1989) Poly(ADP- ribose)polymerase: a novel finger protein. Nucleic Acids Res., 17, 4689-4698.
2. De Murcia, G. and Ménissier de Murcia, J. (1994) Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem., 19, 172-176.
3. De Murcia, G.; Schreiber, V.; Molinete, M.; Saulier, B.; Poch, O.; Masson, M.; Niedergang, C. and Ménissier de Murcia J. (1994a) Structure and function of poly(ADP-ribose) polymerase. Mol. Cell. Biochem., 138, 15-24.
4. Schreiber, V.; Hunting, D.; Trucco, C.; Gowans, B.; Grunwald, D.; De Murcia, G. and de Murcia J.M. (1995) A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage. Proc. Natl. Acad. Sci. USA, 92, 4753-4757.
5. Lindahl, T.; Satoh, M.S.; Poirier G.G. and Klungland A. (1995) Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem. Sci., 20, 405-411.
6. Bürkle, A. (2001) Poly(APD-ribosyl)ation, a DNA damage-driven protein modification and regulator of genomic instability. Cancer Lett., 163, 1-5.
7. Krishnakumar, R. and Kraus, W.L. (2010) The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell, 39, 8-24.
8. De Block, M.; Verduyn, C.; De Brouwer, D. and Cornelissen M. (1995) Poly(ADP-ribose) polymerase in plants affects energy homeostasis, cell death and stress tolerance. Plant J., 41, 95-106.
9. Tao, Z., Gao, P. and Liu, H. W. (2009) Identification of the ADP-ribosylation sites in the PARP-1 automodification domain: analysis and implications. J. Am. Chem. Soc., 131, 14258-14260.
10. Tanuma, S.; Yagi, T. and Johnson G.S. (1985) Endogenous ADP ribosylation of high mobility group proteins 1 and 2 and histone H1 following DNA damage in intact cells. Arch. Biochem. Biophys., 237, 38-42.
11. Rouleau, M.; Aubin, R.A. and Poirier, G.G. (2004) Poly(ADP- ribosyl)ated chromatin domains: access granted. J. Cell Sci., 117, 815-825.
12. Althaus, F.R.; Höfferer, L.; Kleczkowska, H.E.; Malanga, M.; Naegeli, H.; Panzeter, P. and Realini, C. (1993) Histone shuttle driven by the automodification cycle of poly(ADP-ribose) polymerase. Environ. Mol. Mutagen., 22, 278-282.
13. Potaman, V.N.; Shlyakhtenko, L.S.; Oussatcheva E.A.; Lyubchenko, Y.L. and Soldatenkov, V.A. (2005) Specific binding of poly(ADP-ribose) polymerase-1 to cruciform hairpins. J. Mol. Biol., 348, 609-615.
14. Lonskaya, I.; Potaman, V.N.; Shlyakhtenko, L.S.; Oussatcheva, E.A.; Lyubchenko, Y.L. and Soldatenkov, V.A. (2005) Regulation of poly(ADP-ribose) polymerase-1 by DNA structure-specific binding. J. Biol. Chem., 280, 17076-17083.
15. Hauschildt, S.; Scheipers, P.; Bessler, W.; Schwarz, K.; Ullmer, A.; Flad, H.D. and Heine H. (1997) Role of ADP-ribosylation in activated monocytes/macrophages. Adv. Exp. Med. Biol., 419, 249-252.
16. Szabó, C.; Lim, L.H.; Cuzzocrea, S.; Getting, S.J.; Zingarelli, B.; Flower, R.J.; Salzman, A.L. and Perretti, M. (1997) Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts anti-inflammatory effects. J. Exp. Med., 186, 1041-1049.
17. Shall, S. and de Murcia, G. (2000) Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res., 460, 1-15.
18. Damji, N.; Khoo, K.E.; Booker, L. and Browman, G.P. (1986) Influence of the poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on macrophage and granulocyte differentiation of HL-60 cells. Am. J. Hematol., 21, 67-78.
19. Carrillo, A.; Monreal, Y.; Ramírez, P.; Marin, L.; Parrilla, P.; Oliver, F.J. and Yélamos, J. (2004) Transcription regulation of TNF-alpha-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. Nucleic Acids Res., 32, 757-766.
20. Farez, M.F.; Quintana, F.J.; Gandhi, R.; Izquierdo, G.; Lucas, M. and Weiner, H.L. (2009) Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat. Immunol., 10, 958-64.
21. Andreone, T.L.; O'Connor, M.; Denenberg, A.; Hake, P.W. and Zingarelli, B. (2003) Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. J. Immunol., 170, 2113-2120.
22. Pacher, P. and Szabó, C. (2007) Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc. Drug Rev., 25, 235-260.
23. Moroni, F. and Chiarugi, A. (2009) Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. FEBS J., 276, 36-45.
24. Szabó, C. (2005) Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol. Res., 52, 60-71.
25. Oliver, F. J.; Ménissier-de Murcia, J.; Nacci, C.; Decker, P.; Andriantsitohaina, R.; Muller, S.; de la Rubia, G.; Stoclet, J.C. and de Murcia, G. (1999) Resistance to endotoxic shock as a consequence of defective NF-kB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J., 18, 4446-4454.
26. Zingarelli, B.; Salzman, A.L.; Szabò, C. (1998) Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ. Res., 83, 85-94.
27. Oshima, T.; Pavlick, K.P.; Laroux, F.S.; Verma, S.K.; Jordan, P.; Grisham, M.B.; Williams, L. and Alexander, J.S. (2001) Regulation and distribution of MAdCAM-1 in endothelial cells in vitro. Am. J. Physiol. Cell Physiol., 281, C1096-1105.
28. Sharp, C.; Warren, A.; Oshima, T.; Williams, L.; Li, J.H. and Alexander, J.S. (2001) Poly ADP ribose-polymerase inhibitors prevent the upregulation of ICAM-1 and E-selectin in response to Th1 cytokine stimulation. Inflammation, 25, 157-163.
29. Ullrich, O.; Diestel, A.; Eyüpoglu, I.Y.; Nitsch, R. (2001) Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat. Cell Biol., 3, 1035-1042.
30. Ha, H.C. and Snyder, S.H. (1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc. Natl. Acad. Sci. USA, 96, 13978-13982.
31. Esposito, E. and Cuzzocrea, S. (2009) Superoxide, NO, peroxynitrite and PARP in circulatory shock and inflammation. Front. Biosci., 14, 263-296.
32. Halappanavar, S.S.; Rhun, Y.L.; Mounir, S.; Martins, L.M.; Huot, J.; Earnshaw, W.C. and Shah G.M. (1999) Survival and proliferation of cells expressing caspase-uncleavable Poly(ADP-ribose) polymerase in response to death-inducing DNA damage by an alkylating agent. J. Biol. Chem., 274, 37097-37104.
33. Malireddi, R.K.; Ippagunta, S.; Lamkanfi, M. and Kanneganti, T.D. (2010) Cutting edge: proteolytic inactivation of poly(ADP-ribose) polymerase 1 by the Nlrp3 and Nlrc4 inflammasomes. J. Immunol, 185, 3127-3130.
34. Zhu, P.; Martinvalet, D.; Chowdhury, D.; Zhang, D.; Schlesinger, A. and Lieberman, J. (2009) The cytotoxic T lymphocyte protease granzyme A cleaves and inactivates poly(adenosine 5'-diphosphate-ribose) polymerase- 1. Blood, 114, 1205-1216.
35. Yu, S.W.; Wang, H.; Poitras, M.F.; Coombs, C; Bowers, W.J.; Federoff, H.J.; Poirier, G.G.; Dawson, T.M. and Dawson, V.L. (2002) Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science, 297, 259-263.
36. Yang, N.; Gong, F.; Sun, L.; Yang, D.; Han, X.; Ma, C. and Sun, Y. (2010) Poly (ADP-ribose) polymerase-1 binds to BCL2 major breakpoint region and regulates BCL2 expression. J. Cell Biochem., 110, 1208-1218.
37. Hassa, P.O.; Covic, M.; Hasan, S.; Imhof, R. and Hottiger, M.O. (2001) The enzymatic and DNA binding activity of PARP-1 are not required for NF-kB coactivator function. J. Biol. Chem., 276, 45588-45597.
38. Zerfaoui, M.; Errami, Y.; Naura, A.S.; Suzuki, Y.; Kim, H.; Ju, J.; Liu, T.; Hans, C.P.; Kim, J.G.; Abd Elmageed, Z.Y.; Koochekpour, S.; Catling, A. and Boulares, A.H. (2010) Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kB upon TLR4 stimulation. J. Immunol, 185, 1894-1902.
39. Hassa, P.O.; Buerki, C; Lombardi, C; Imhof, R. and Hottiger, M.O. (2003) Transcriptional coactivation of nuclear factor-kB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J. Biol. Chem., 278, 45145-45153.
40. Huang, D.; Yang, C.Z.; Yao, L.; Wang, Y.; Liao, Y.H. and Huang, K. (2008) Activation and overexpression of PARP-1 in circulating mononuclear cells promote TNFa and IL-6 expression in patients with unstable angina. Arch. Med. Res., 39, 775-784.
41. Erdélyi, K.; Bakondi, E.; Gergely, P.; Szabó, C. and Virág, L. (2005) Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation. Cell. Mol Life Sci., 62, 751-759.
42. Aldinucci, A.; Gerlini, G.; Fossati, S.; Cipriani, G.; Ballerini, C; Biagioli, T.; Pimpinelli, N.; Borgognoni, L.; Massacesi, L.; Moroni, F. and Chiarugi, A. (2007) A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. J. Immunol, 179, 305-312.
43. King, S.L.; McNerney, R.; Whitley, G.S. and Johnstone, A.P. (1989) Differential role for ADP-ribosylation in gene expression during the activation of T lymphocytes by various stimuli. Immunology, 67, 258-262.
44. + regulatory T cells in poly(ADP-Ribose) polymerase-1 deficiency. J. Immunol, 184, 3470-3477.
45. Ambrose, H.E.; Willimott, S.; Beswick, R.W.; Dantzer, F.; de Murcia, J.M.; Yelamos, J. and Wagner, S.D. (2009) Poly(ADP-ribose) polymerase-1 (Parp-1)-deficient mice demonstrate abnormal antibody responses. Immunology, 127, 178-186.
46. Shockett, P. and Stavnezer, J. (1993) Inhibitors of poly(ADP-ribose) polymerase increase antibody class switching. J. Immunol, 151, 6962-6976.
47. Olabisi, O.A.; Soto-Nieves, N.; Nieves, E.; Yang, T.T.; Yang, X.; Yu, R.Y.; Suk, H.Y.; Macian, F. and Chow, C.W. (2008) Regulation of transcription factor NFAT by ADP-ribosylation. Mol. Cell. Biol, 28, 2860-2871.
48. Valdor, R.; Schreiber, V.; Saenz, L.; Martínez, T.; Muñoz-Suano, A.; Dominguez-Villar, M.; Ramírez, P.; Parrilla, P.; Aguado, E.; García-Cózar, F. and Yélamos, J. (2008) Regulation of NFAT by poly(ADP-ribose) polymerase activity in T cells. Mol. Immunol, 45, 1863-1871.
49. Saenz, L.; Lozan, J.J.; Valdor, R.; Baroja-Mazo, A.; Ramirez, P.; Parrilla, P.; Aparicio, P.; Sumoy, L. and Yélamos, J. (2008) Transcriptional regulation by poly (ADP-ribose) polymerase-1 during T cell activation. BMC Genomics, 9, 171-181.
50. Macian, F. (2005) NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol, 5, 472-484.
51. Pioli, C; Gatta, L.; Frasca, D. and Doria, G. (1999) Cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibits CD28-induced IkappaBalpha degradation and RelA activation. Eur. J. Immunol., 29, 856-863.
52. Gatta, L.; Calviello, G.; Di Nicuolo, F.; Pace, L.; Ubaldi, V.; Doria, G. and Pioli, C. (2002) Cytotoxic T lymphocyte-associated antigen-4 inhibits integrin-mediated stimulation. Immunology, 107, 209-216.
53. Bennett, C.L.; Christie, J.; Ramsdell, F.; Brunkow, M.E.; Ferguson, P.J.; Whitesell, L.; Kelly, T.E.; Saulsbury, F.T.; Chance, P.F. and Ochs, H.D. (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet., 27, 20-21.
54. Hori, S.; Nomura, T. and Sakaguchi, S. (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science, 299, 1057-1061.
55. Thorén, F.B.; Romero, A.I. and Hellstrand, K. (2006) Oxygen radicals induce poly(ADP-ribose) polymerase-dependent cell death in cytotoxic lymphocytes. J. Immunol., 176, 7301-7307.
56. Kono, K.; Salazar-Onfray, F.; Petersson, M.; Hansson, J.; Masucci, G.; Wasserman, K.; Nakazawa, T.; Anderson, P. and Kiessling, R. (1996) Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur. J. Immunol., 26, 1308-1313.
57. Bauernhofer, T.; Kuss, I.; Henderson, B.; Baum, A.S. and Whiteside, T.L. (2003) Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur. J. Immunol., 33, 119-124.
58. Morrison, C.; Smith, G.C.; Stingl, L.; Jackson, S.P.; Wagner, E.F. and Wang, Z.Q. (1997) Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis. Nat. Genet., 17, 479-482.
59. Maruyama, T.; Nara, K.; Yoshikawa, H. and Suzuki, N. (2007) Txk, a member of the non-receptor tyrosine kinase of the Tec family, forms a complex with poly(ADP-ribose) polymerase 1 and elongation factor 1alpha and regulates interferon-gamma gene transcription in Th1 cells. Clin. Exp. Immunol., 147, 164-175.
60. García, S.; Bodaño, A.; González, A.; Forteza, J.; Gómez-Reino, J.J. and Conde, C. (2006) Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice. Arthritis Res. Ther., 8, R14.
61. Gonzalez-Rey, E.; Martínez-Romero, R.; O'Valle, F.; Aguilar-Quesada, R.; Conde, C.; Delgado, M. and Oliver, F. (2007) Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response. PLoS One, 2, e1071.
62. Pascual, M.; López-Nevot, M.A.; Cáliz, R.; Ferrer, M.A.; Balsa, A.; Pascual-Salcedo, D. and Martín, J. (2003) A poly(ADP-ribose) polymerase haplotype spanning the promoter region confers susceptibility to rheumatoid arthritis. Arthritis Rheum., 48, 638-641.
63. Lee, K.A.; Bang, S.Y.; Park, B.L.; Kim, J.H.; Shin, H.D. and Bae, S.C. (2010) Lack of association between Poly(ADP-ribose) polymerase (PARP) polymorphisms and rheumatoid arthritis in a Korean population. Rheumatol. Int., [Epub ahead of print]
64. Sánchez-Fidalgo, S.; Villegas, I.; Martín, A.; Sánchez-Hidalgo, M. and Alarcón de Lastra, C. (2007) PARP inhibition reduces acute colonic inflammation in rats. Eur. J. Pharmacol., 563, 216-223.
65. Mazzon, E.; Dugo, L.; Li, J.H.; Di Paola, R.; Genovese, T.; Caputi, A.P.; Zhang, J. and Cuzzocrea S. (2002) GPI 6150, a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat. Biochem. Pharmacol., 64, 327-337.
66. Mabley, J.G.; Jagtap, P.; Perretti, M.; Getting, S.J.; Salzman, A.L.; Virág, L.; Szabó, E.; Soriano, F.G.; Liaudet, L.; Abdelkarim, G.E.; Haskó, G.; Marton, A.; Southan, G.J. and Szabó C. (2001) Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase. Inflamm. Res., 50, 561-569.
67. Zingarelli, B.; O'Connor, M. and Hake, P.W. (2003) Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways in colitis. Eur. J. Pharmacol., 469, 183-194.
68. Jijon, H.B.; Churchill, T.; Malfair, D.; Wessler, A.; Jewell, L.D.; Parsons, H.G. and Madsen, K.L. (2000) Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am. J. Physiol. Gastrointest. Liver Physiol., 279, G641-G651.
69. Popoff, I.; Jijon, H.; Monia, B.; Tavernini, M.; Ma, M.; McKay, R. and Madsen, K. (2002) Antisense oligonucleotides to poly(ADP-ribose) polymerase-2 ameliorate colitis in interleukin-10-deficient mice. J. Pharmacol. Exp. Ther., 303, 1145-1154.
70. Cuzzocrea, S.; Mazzon, E.; Genovese, T.; Crisafulli, C.; Min, W.K.; Di Paola, R.; Muià, C.; Li, J.H.; Malleo, G.; Xu, W.; Massuda, E.; Esposito, E.; Zhang, J. and Wang Z.Q. (2007) Role of poly(ADP-ribose) glycohydrolase in the development of inflammatory bowel disease in mice. Free Radic. Biol. Med., 42, 90-105.
71. Toller, I.M.; Altmeyer, M.; Kohler, E.; Hottiger, M.O. and Müller, A. (2010) Inhibition of ADP ribosylation prevents and cures helicobacter-induced gastric preneoplasia. Cancer Res., 70, 5912-5922.
72. Scott, G.S.; Kean, R.B.; Mikheeva, T.; Fabis, M.J.; Mabley, J.G.; Szabó, C. and Hooper, D.C. (2004) The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide. HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J. Pharmacol. Exp. Ther., 310, 1053-1061.
73. Chiarugi, A. (2002) Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br. J. Pharmacol., 137, 761-770.
74. Selvaraj, V.; Soundarapandian, M.M.; Chechneva, O.; Williams, A.J.; Sidorov, M.K.; Soulika, A.M.; Pleasure, D.E. and Deng, W. (2009) PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis. J. Biol. Chem., 284, 26070-26084.
75. Brunyánszki, A.; Hegedus, C.; Szántó, M.; Erdélyi, K.; Kovács, K.; Schreiber, V.; Gergely, S.; Kiss, B.; Szabó, E.; Virág, L. and Bai, P. (2010) Genetic ablation of PARP-1 protects against oxazolone-induced contact hypersensitivity by modulating oxidative stress. J. Invest. Dermatol., 130, 2629-2637.
76. Havranek, T.; Aujla, P.K.; Nickola, T.J.; Rose, M.C. and Scavo, L.M. (2010) Increased poly(ADP-ribose) polymerase (PARP)-1 expression and activity are associated with inflammation but not goblet cell metaplasia in murine models of allergen-induced airway inflammation. Exp. Lung Res., 36, 381-389.
77. Espinoza, L.A.; Smulson, M.E. and Chen, Z. (2007). Prolonged poly(ADP-ribose) polymerase-1 activity regulates JP-8-induced sustained cytokine expression in alveolar macrophages. Free Rad. Biol. Med., 42, 1430-1440.
78. Virág, L. (2005) Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol. Res., 52, 83-92.
79. Oumouna, M.; Datta, R.; Oumouna-Benachour, K.; Suzuki, Y.; Hans, C.; Matthews, K.; Fallon, K. and Boulares, H. (2006) Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5. J. Immunol., 177, 6489-6496.
80. Tezcan, G.; Gurel, C.B.; Tutluoglu, B.; Onaran, I. and Kanigur-Sultuybek, G. (2009) The Ala allele at Val762Ala polymorphism in poly(ADP-ribose) polymerase-1 (PARP-1) gene is associated with a decreased risk of asthma in a Turkish population. J. Asthma, 46, 371-374.
81. Ferraris, D.V. (2010) Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J. Med. Chem., 53, 4561-4584.
82. Giansanti, V.; Donà, F.; Tillhon, M. and Scovassi, A. (2010) PARP inhibitors: new tools to protect from inflammation. Biochem. Pharmacol., 80, 1869-1877.
83. Mégnin-Chanet, F.; Bollet, M.A. and Hall, J. (2010) Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell Mol. Life Sci., 67, 3649-3662.
84. Weseler, A.R.; Geraets, L.; Moonen, H.J.; Manders, R.J.; van Loon, L.J.; Pennings, H.J.; Wouters, E.F.; Bast, A. and Hageman, G.J. (2009) Poly (ADP-ribose) polymerase-1-inhibiting flavonoids attenuate cytokine release in blood from male patients with chronic obstructive pulmonary disease or type 2 diabetes. J. Nutr., 139, 952-957.
85. Shrikhande, G.; Khaodhiar, L.; Scali, S.; Lima, C.; Hubbard, M.; Dudley, K.; Ganda, O.; Ferran, C. and Veves, A. (2006) Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. J. Vasc. Surg., 43, 760-770.
86. Morrow, D.A.; Brickman, C.M.; Murphy, S.A.; Baran, K.; Krakover, R.; Dauerman, H.; Kumar, S.; Slomowitz, N.; Grip, L.; McCabe, C.H. and Salzman, A.L. (2009) A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharma-cokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J. Thromb. Thrombolysis, 27, 359-364.